Table 3.

Treatment and clinical outcomes of 31 enrolled patients.

Variable	Dipyridamole group (n = 14)	Control group (n = 17)
Group
—Non-severe no./Severe no./Critical no.	4/8/2	3/12/2
Treatment
Oxygen therapy—no. (%)	14 (100.0%)	17 (100.0%)
Mechanical ventilation—no. (%)	2 (14.3%)	2 (11.8%)
—no. of non-severe cases (%)	0	0
—no. of severe cases (%)	0	1/12 (8.3%)
—no. of critical cases (%)	2/2 (100%)	1/2 (50%)
Antibiotic treatment—no. (%)	6 (42.9%)	10 (58.8%)
Antifungal treatment—no. (%)	0	0
Antiviral treatment—no. (%)	14 (100.0%)	17 (100.0%)
Glucocorticoids—no. (%)	14 (100.0%)	17 (100.0%)
Outcome
Discharge rate—no. (%)	11/14 (78.6%)	7/17 (41.2%)
—no. of non-severe cases (%)	4/4 (100%)	3/3 (100%)
—no. of severe cases (%)	7/8 (87.5%)	4/12 (33.3%)
—no. of critical cases (%)	0	0
Average time for viral clearance (days)	–	–
—severe cases (%)	15.4	17.0
Remission rate—no. (%)	2/14 (14.3%)	2/17 (11.8%)
—no. of severe cases (%)	1/8 (12.5%)	2/12 (16.7%)
—no. of critical cases (%)	1/2 (50%)	0
Progression rate—no. (%)	0	1/17 (5.9%)
—no. of non-severe cases (%)	0	0
—no. of severe cases (%)	0	1/12 (8.3%)
Death rate—no. (%)	1/14 (7.1%)	4/17 (23.5%)
—no. of severe cases (%)	0	2/12 (8.3%)
—no. of critical cases (%)	1/2 (50%)	2/2 (100%)